(Bloomberg) — A steady flow of small deals makes sense for Roche Holding A.G., and the Swiss drugmaker is in no hurry to buy the rest of Chugai Pharmaceutical Co. that it doesn’t already own, Chief Financial Officer Alan Hippe said.
Roche, the world’s biggest maker of cancer drugs, will continue to “fill gaps” in its portfolio and invest in treatments for Alzheimer’s disease, Hippe said in an interview in San Francisco, where health executives are attending a JPMorgan Chase & Co. annual conference.
The Swiss drugmaker said this week it will pay more than $1 billion for a majority stake in Foundation Medicine Inc. to get access to genetic tests for tumors and develop new treatments for fighting cancer. That follows purchases last year of InterMune Inc. for about $8.3 billion and Seragon Pharmaceuticals Inc., a developer of breast cancer drugs, for as much as $1.7 billion.
See also: What genetic testing means for life insurers.
“We want to build the pipeline in pharma, we want to fill gaps,” Hippe said. “This continuous flow of rather small acquisitions makes total sense.”